Influenza vaccine
The present invention relates to a composition comprising at least one ISCOM complex and at least one ectodomain from at least one hemagglutinin (HA) domain and at least one ectodomain from at least one neuraminidase (NA) domain from one or more influenza virus, wherein the extodomains represent ectodomains isolated from the influenza virus. The invention also regards a kit. The composition may be used as an immune stimulating medicine, immune modulating pharmaceutical or a vaccine e.g. against influenza for vertebrates, e.g. birds and mammals.
1. Composition comprising at least one ISCOM matrix and at least one isolated ectodomain from at least one hemagglutinin domain and at least one isolated ectodomain from at least one neuraminidase domain from one or more influenza virus, wherein the ectodomains represent ectodomains isolated from the influenza virus, the isolated ectodomains being isolated from the rest of the hemagglutinin and neuraminidase proteins; wherein the ectodomains are present in the composition at a ratio of neuraminidase ectodomain to hemagglutinin ectodomain that is greater than that of wild type influenza virus; and
wherein the at least one ISCOM matrix comprises at least one saponin and at least one lipid.
2. The composition according to claim 1 , wherein one or more of the isolated ectodomains from at least one hemagglutinin domain and one or more of the isolated ectodomains from at least one neuraminidase domain are presented as hybrid proteins comprising at least one protein or portion thereof not of influenza virus.
3. The composition according to claim 1 , wherein one or more of the isolated ectodomains from at least one hemagglutinin domain and one or more of the isolated ectodomains from at least one neuraminidase domain are a head domain.
4. The composition according to claim 1 , wherein the influenza virus is chosen from a sub serotype of influenza from HxNy, wherein x is 1-16 and y is 1-9.
5. The composition according to claim 4 , wherein the influenza virus is chosen from the group consisting of 1918 H1N1 influenza virus (A/South Carolina/1/18), 2004 H5N1 influenza virus (A/Vietnam/1203/04), H1N1 influenza virus (A/California/07/2009), H1N1 influenza virus (A/California/04/2009), H1N1 influenza virus (A/California/09/2009), H1N1 influenza virus (A/Kentucky/UR06-0258/2007), and H5N1 influenza virus (A/turkey/Turkey/1/2005).
6. The composition according to claim 1 , wherein the composition comprises 1-5 ectodomains from at least one hemagglutinin domain and 1-5 head domains from at least one neuraminidase domain.
7. The composition according to claim 6 , wherein the at least one hemagglutinin ectodomain is chosen from the trimeric HA ectodomain (a.a. 17-522) of the H1N1 influenza virus (A/California/09/2009).
8. The composition according to claim 6 , wherein the at least one neuraminidase head domain is chosen from the tetrameric NA head domain (a.a. 75-469) of the H1N1 influenza virus (A/California/09/2009).
9. The composition according to claim 1 , further comprising at least one of an additive, an excipient, and a further adjuvant.
10. A composition according to claim 1 for use as an immune stimulating medicine, an immune modulating pharmaceutical, or a vaccine against influenza for a vertebrate.
11. The composition according to claim 10 , wherein the vertebrate is selected from the group consisting of human, cat, dog, horse, bird, cattle, bovine species, swine, sheep, goat, ferret, and mink.
12. A kit comprising at least two compartments, wherein one compartment comprises a composition comprising at least one ISCOM matrix and at least one isolated ectodomain from at least one hemagglutinin domain and at least one isolated ectodomain from at least one neuraminidase domain from one or more influenza virus and the other compartment comprises instructions for use, wherein the ectodomains represent ectodomains isolated from the influenza virus, the isolated ectodomains being isolated from the rest of the hemagglutinin and neuraminidase proteins, wherein the ectodomains are present in the composition at a ratio of neuraminidase ectodomain to hemagglutinin ectodomain that is greater than that of wild type influenza virus; and
wherein the at least one ISCOM matrix comprises at least one saponin and at least one lipid.
13. The composition of claim 1 wherein the ISCOM matrix comprises separate ISCOM matrix particles containing Fraction A and Fraction C.
14. The composition of claim 13 wherein the ISCOM matrix comprises from 5% to 50% (w/w) Fraction C ISCOM matrix particles with the remainder Fraction A ISCOM matrix particles.
15. The composition according to claim 13 wherein the ISCOM matrix comprises up to 30% (w/w) Fraction C ISCOM matrix particles with the remainder Fraction A ISCOM matrix particles.
16. The composition according to claim 14 wherein the ISCOM matrix comprises 15% (w/w) Fraction C ISCOM matrix particles and 85% Fraction A ISCOM matrix particles.
17. The kit of claim 12 wherein the ISCOM matrix comprises separate ISCOM matrix particles containing Fraction A and Fraction C.
18. The kit of claim 17 wherein the ISCOM matrix comprises from 5% to 50% (w/w) Fraction C ISCOM matrix particles with the remainder Fraction A ISCOM matrix particles.
19. The kit according to claim 17 wherein the ISCOM matrix comprises up to 30% (w/w) Fraction C ISCOM matrix particles with the remainder Fraction A ISCOM matrix particles.
20. The kit according to claim 18 wherein the ISCOM matrix comprises 15% (w/w) Fraction C ISCOM matrix particles and 85% Fraction A ISCOM matrix particles.